A study evaluating tovorafenib (DAY101) monotherapy versus standard of care chemotherapy in patients with Low-Grade Glioma (LGG).
Study Details
Internal Title:
Day101-002
PCH IRB Number:
IRB-23-073
Clinical Trials Government Identifier:
NCT05566795
Diagnoses & Treatments:
LGG, Low-Grade Glioma, Tovorafenib, DAY101, Cancer
Study Type:
Clinical Trial
Eligibility:
0-17 Years Old, Low-Grade Glioma Diagnosis
Enrollment Status:
Open
Phase:
III